Navigation Links
Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World
Date:5/6/2010

is, Haemoplilus influenza type b infection and hepatitis B. Quinvaxem(R) is ready for use without further preparation steps by healthcare workers in the field, which offers major healthcare advantages for these countries with a challenging infrastructure and hygiene problems.

This latest order brings the overall value of tenders awarded to Crucell for the period of 2010-2012 to $410 million. This is in addition to the $500 million obtained over the tender period 2007-2009. They bring the total value of contracts awarded since the launch of Quinvaxem(R) at the end of 2006 to $910 million. During the first tender round in 2006, Crucell was initially awarded $230 million (December 2006) and received additional incremental awards of $130 million and $140 million in May and September 2008, respectively.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the US Securities and Exchange Commission on April 7, 2010, in the section entitled 'Risk Factors'. The Company prepares its financial statements under International Financial Reporting Standards (IFRS).

About Crucell

Crucell N.V. (NYSE Euronext, NASDAQ: CRXL<
'/>"/>

SOURCE Crucell N.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
2. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
3. DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
4. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... West Chester, OH (PRWEB) November 25, 2014 ... International Holdings, has joined the Graphel Carbon Products team ... experience in sales, marketing, and customer service for the ... to add Miles to our team,” stated Dave Trinkley, ... Products. “His wide range of experience in the ...
(Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
(Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
(Date:11/24/2014)... Baltimore, MD (PRWEB) November 24, 2014 ... recruiting underrepresented patient populations into clinical trials at ... Maryland. , “Continental was created with the ... trials play a fundamental role in medical advances," ... the Tuskegee syphilis experiment to the immortal cell ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... 14 Quest Diagnostics,Incorporated (NYSE: DGX ), ... services, announced that it is scheduled to speak,at ... Care Conference on,Tuesday, March 18, 2008, at the ... is scheduled to begin at,8:45 a.m. Eastern Time., ...
... a medical device company focused on developing products for,minimally ... O,Boyle, Executive Vice President and Chief Financial Officer,is scheduled ... Conference at the Loews Miami Beach Hotel in Miami ... ET., A live Web cast of the presentation ...
... Bionovo, Inc.,(Nasdaq: BNVI ) announced today the ... Directors. Mr. Drapeau has extensive financial,management experience with ... quite excited to have access to Lou,s expertise," ... is particularly well versed,in the unique financial scenarios ...
Cached Biology Technology:Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3Louis Drapeau Joins Bionovo's Board of Directors 2Louis Drapeau Joins Bionovo's Board of Directors 3
(Date:11/3/2014)... that low birth weight and preterm birth are linked ... adulthood. Findings published in the American College of Rheumatology ... that low birth weight and pre-term babies were not ... as adults. , According to the ACR, 27 ... with clinical OA. Symptoms of OA range from mild ...
(Date:11/2/2014)... of a bold quest to rid the world entirely ... announced an award of US$156 million to PATH to ... new vaccines that will interrupt the cycle of malaria ... agenda. Such vaccines would ensure that parasite reintroduction is ... bed net." , This approach to developing malaria ...
(Date:11/2/2014)... into a bar and bump into a biologist . . ... some late-night nerd sketch, researchers have taken this premise and ... namely, finding meaning in the rising oceans of genomic data. ... mutations that genome-wide studies are publishing at a dizzying rate. ... the signal from the noise (and there is no shortage ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... funded by the National Institute of Allergy and Infectious ... (NIH), have engineered a powerful inhibitor of anthrax toxin ... "This novel approach to the design of anthrax antitoxin ... it may have in anthrax treatment, but also because ...
... have discovered the gene responsible for a type of ... coordination. , This is the first neurodegenerative disease shown ... spectrin which plays an important role in the maintaining ... historical implications as well--the gene was identified in an ...
... study of the travels of the malaria parasite Plasmodium ... Paris found the parasites developing in an unexpected place: ... lymph nodes almost certainly has implications for the mammalian ... Institute (HHMI) international research scholar who led the study. ...
Cached Biology News:Scientists design potent anthrax toxin inhibitor 2Scientists design potent anthrax toxin inhibitor 3U of MN researchers identify ataxia gene 2Malaria parasites develop in lymph nodes 2Malaria parasites develop in lymph nodes 3
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: